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Abstract
Background: A strong genetic influence by the MHC class II region has been reported in sarcoidosis, however in
many studies with different results. This may possibly be caused by actual differences between distinct ethnic
groups, too small sample sizes, or because of lack of accurate clinical subgrouping.
Subjects and methods: In this study we HLA typed a large patient population (n = 754) recruited from one single
centre. Patients were sub-grouped into those with Löfgren’s syndrome (LS) (n = 302) and those without (non-
Löfgren’s) (n = 452), and the majority of them were clinically classified into those with recovery within two years
(resolving) and those with signs of disease for more than two years (non-resolving). PCR was used for
determination of HLA-DRB1 alleles. Swedish healthy blood donors (n = 1366) served as controls.
Results: There was a dramatic difference in the distribution of HLA alleles in LS compared to non-LS patients (p =
4×1 0
-36). Most notably, DRB1*01, DRB1*03 and DRB1*14, clearly differed in LS and non-LS patients. In relation to
disease course, DRB1*07, DRB1*14 and DRB1*15 generally associated with, while DRB1*01 and DRB1*03 protected
against, a non-resolving disease. Interestingly, the clinical influence of DRB1*03 (good prognosis) dominated over
that of DRB1*15 (bad prognosis).
Conclusions: We found several significant differences between LS and non-LS patients and we therefore suggest
that genetic association studies in sarcoidosis should include a careful clinical characterisation and sub-grouping of
patients, in order to reveal true genetic associations. This may be particularly accurate to do in the heterogeneous
non-LS group of patients.
Background
Sarcoidosis is an inflammatory disease of unknown aetiol-
ogy. A genetic influence has been suggested by reports
showing different susceptibilities and clinical manifesta-
tions between distinct ethnic groups [1]. In addition
genetic linkage analyses have pointed out a significant
linkage for the major histocompatibility complex (MHC)
region [2], but also with minor peaks in specific regions of
some other chromosomes [3]. One recently published gen-
ome wide association study described an association with
the gene coding for Annexin A11, a protein with several
important functions, including for apoptosis [4].
Sarcoidosis is thus influenced by a multitude of genes,
however with the strongest associations described within
the HLA-region. Several specific HLA alleles clearly
associate with disease risk, and in a few cases also asso-
ciations with disease phenotype e.g. uveitis [5] have
been described. The HLA-DRB1*03/DQB1*02 haplotype
has repeatedly been associated with Löfgren’ss y n d r o m e
[6-12] i.e. a distinct form of sarcoidosis characterised by
an acute onset with bilateral hilar lymphadenopathy
(BHL) and in some cases parenchymal infiltrates,
e r y t h e m an o d o s u m( E N )a n d / o r bilateral ankle arthritis
or distinct periarticular inflammation, and usually fever
[13]. Our own group recently reported a strong influ-
ence by the DRB1*03 allele on the disease course in
patients with Löfgren’s syndrome, with complete recov-
ery within two years in almost all DRB1*03 positive
patients, but only in about half of the DRB1*03 negative
patients [14]. Patients with Löfgren’s syndrome may
in fact constitute a disease entity by its own, and a
recent report on specific associations between a CCR2
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esis [15].
However, because of genetic differences, it may be dif-
ficult to compare the importance of specific HLA-DR
alleles for the disease between various ethnic groups.
The HLA-DRB1*03 allele is for example rather common
in e.g. Scandinavia but extremely uncommon in Japa-
nese individuals, so that the common association in
Caucasians between DRB1*03 and an acute disease is
rare in Japanese [16]. Most previous studies did not
report distinct clinical sub-grouping of patients, but for
example in our region, patients with Löfgren’s syndrome
make up 35-40% of all our patients and they will there-
fore contribute substantially to any genetic association.
I nt h ep r e s e n ts t u d yw et h e r e f o r es u b - g r o u p e do u r
patients into those with Löfgren’s syndrome (LS), and
those without Löfgren’s syndrome (non-LS), and ana-
lysed any correlations between distinct HLA-DRB1
alleles and the risk for disease as well as the disease
course. We studied a large group of sarcoidosis patients
f r o mo n es i n g l ec e n t r e( K a r o l i n s k aU n i v e r s i t yH o s p i t a l
in Stockholm, Sweden).
Materials and methods
Study subjects
Altogether 754 patients were included in this study, 452
classified as non-Löfgren’s syndrome (non-LS) and 302
as Löfgren’s syndrome (LS) patients (se Table 1 for
demographics).
All patients were referred to us for making the pri-
mary diagnosis through our examinations and investiga-
tions, and further management according to our
routines at the outpatient clinic at the Pulmonary Divi-
sion at the Karolinska University Hospital, Solna, Swe-
den. The vast majority of patients was seen by one of
the authors (A.E), essentially from 1994 and onwards,
and only in a few cases data was collected through
records. Chest radiographies were evaluated by one of
the authors (K.C), who is subspecialized in chest
radiology with long experience of interstitial pulmonary
disease. Patients were diagnosed with sarcoidosis
through typical clinical manifestations, findings at
bronchoscopy with bronchoalveolar lavage (BAL)
including an elevated CD4/CD8 BAL cell ratio, and
positive biopsies, using the criteria as outlined by the
World Association of Sarcoidosis and other Granuloma-
tous disorders (WASOG) [17].
Through the clinical characterisation, patients were
grouped into those with Löfgren’s syndrome, i.e. with
an acute onset with bilateral hilar lymphadenopathy
(BHL) and in some cases parenchymal infiltrates,
erythema nodosum (EN) and/or bilateral ankle arthritis
or distinct periarticular inflammation, and usually fever
(n = 302) [18]. The remaining group of patients were
classified as “non-Löfgren’s” (n = 452). Moreover, 724
of the patients were followed for at least two years and
grouped into those with a resolving or a non-resolving
disease. A resolved disease was classified in patients
who had normalised radiography and pulmonary lung
function, no symptoms, and normal biochemical para-
meters. A non-resolved disease was defined in patients
with signs of persistence or progress of chest radio-
graphic changes or of deteriorating pulmonary function
tests, with clinical signs of disease activity with symp-
toms (usually extreme fatigue, cough, dyspnea, or in
patients who developed symptoms from extrathoracic
organs that were caused by sarcoidosis). Thus a number
of parameters were evaluated in order to correctly clas-
sify the patients. The non-resolving group may include
patients with a slowly resolving, a chronic stable, or a
chronic progressive disease. This whole group is of
great importance to include and further sub-group in
future studies.
The control group consisted of 1.366 consecutively
collected Scandinavian blood donors, 815 female and
551 males, all residents of the Stockholm area.
All included subjects gave their informed consent for
participation in the study, which was approved by the
Table 1 Patients’ and controls’demographics
All patients Non Löfgren Löfgren’s syndrome
Female/male 330/424 194/258 136/166
*Age (years) 38 (19-77) 40 (19-77) 36 (23-71)
**Radiografic stage
0/I/II/III/IV
39/368/241/84/22 38/135/173/84/22 1/233/68/0/0
Never smokers 447 250 197
***Ex-smokers 216 154 62
Current smokers 90 48 42
****Treatment/no treatment 309/445 243/209 66/236
*values show median (min - max)
**one LS patient had BHL on disease onset but at the time for bronchoscopy and BAL the radiographic picture was classified as normal
***complete smoke stop since at least one year before analysis
****show number of patients on treatment with oral steroids or other immunosuppressives, including patients where treatment was initiated after bronchoscopy
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Hospital.
Preparation of DNA and HLA typing
All patients were HLA-typed. Genomic DNA was
extracted from whole blood samples, and HLA-DRB1
alleles were determined in every patient using the PCR-
SSP technique [19]
Statistical analyses
The effect of carriage of each allel was assessed by logis-
tic regression in each subpopulation. DRB1*13 was used
as a baseline comparator since this allele had approxi-
mately the same frequency in all subpopulations of
cases and controls (see Table 1). The least common
alleles were joined into an X term, thus including
DRB1*09, DRB1*10, DRB1*12 and DRB1*16. It should
be noted that odds ratios obtained in a logistic regres-
sion framework are adjusted for all the other alleles
included in the model. Correction for multiple testing
was performed for all tests simulaneously using false
discovery rate (FDR) restriction, where a FDR of less
than 5% was considered acceptable [20].
The difference in distribution of carriage of alleles in
different sub-groups was assessed with a Χ
2 test. The
non-parametric Mann Whitney test was used to com-
pare age in the patient subgroups.
Results
The HLA-DRB1 allele distribution frequencies were
found to be significantly different in patients with LS
versus non-LS patients (p = 4 × 10
-36). We therefore
analysed the DRB1 allele distibution in the entire group
of sarcoidosis patients but also separately in LS and
non-LS patients. In each of these patient groups, we
moreover classified patients as resolving, with no signs
of disease at two years after disease onset, or as non-
resolving, with signs of disease at two years. Our data
was compared with a large group of Swedish healthy
controls (n = 1366).
The allele carrier frequencies for all patients and con-
trols are shown in Table 2. As can be seen, the frequency
of DRB1*13 was quite constant across all patient groups,
and it was therefore chosen as a baseline comparator.
Most of our significant findings are from DRB1 alleles
that are frequently occurring. Thus DRB1*01, DRB1*03
and DRB1*15 are normally found in 22, 24 and 30% of
healthy controls, respectively, and the substantial differ-
ent frequencies in the patient groups will therefore be of
importance for large numbers of individuals.
All patients (n = 754)
In the complete group of patients, the strongest associa-
tion was found for HLA-DRB1*03, with an OR of 1.91,
p=1×1 0
-6. Also DRB1*14 (OR 1.79, p = 0.017) asso-
ciated with disease, with a similar tendency for DRB1*15
(OR 1.32, p = 0.067). In contrast, DRB1*01 protected
against disease (OR 0.61, p = 0.003), with a similar
trend for DRB1*04 (OR 0.77, p = 0.086) (Table 3).
The distribution of alleles between resolving and non
resolving disease was significantly different (p = 3 × 10
-39),
and these two groups were thus analysed separately.
Among non-resolving patients (n = 399), the strongest
associations were found for DRB1*01 and DRB1*03, both
clearly protecting against a non-resolving disease (OR
0.41, p = 3 × 10
-5 and OR 0.45, p = 1 × 10
-4 respectively).
Table 2 Allele carrier frequencies (%) in controls (n = 1366), in all patients (n = 754), in non-Löfgren’s patients
(n = 452) and in Löfgren’s syndrome patients (n = 302).
DRB1
*01 *03 *04 *07 *08 *09 *10 *11 *12 *13 *14 *15 *16 x
Controls 22.3 23.8 34.3 15.4 10.5 2.9 1.8 11.4 3.8 26.7 4.6 29.7 1.3 9.7
All patients 13.9 37.5 27.3 11.7 8.1 2.7 1.7 13.0 4.6 25.6 7.4 34.6 0.7 9.7
*Non-resolving 10.5 12.0 29.3 15.8 11.0 3.3 2.3 15.8 6.0 25.8 10.3 43.1 0.8 12.3
Resolving 16.9 66.2 25.5 6.5 5.2 2.2 1.2 10.5 2.8 25.2 4.6 24.9 0.3 6.5
Non-Löfgrens 10.2 16.8 30.8 14.4 10.8 3.1 2.0 17.0 5.5 26.3 9.1 39.4 0.7 11.3
Non-resolving 9.0 13.0 28.5 16.4 11.6 3.1 2.3 17.2 6.5 25.7 10.2 41.0 0.8 12.7
Resolving 12.0 30.4 38.0 7.6 8.7 3.3 1.1 17.4 2.2 29.4 5.4 33.7 0.0 6.5
Löfgrens 19.5 68.5 22.2 7.6 4.0 2.0 1.3 7.0 3.3 24.5 5.0 27.5 0.7 7.3
Non-resolving 22.2 4.4 35.6 11.1 6.7 4.4 2.2 4.4 2.2 26.7 11.1 60.0 0.0 8.9
Resolving 18.9 80.3 20.6 6.0 3.9 1.7 1.3 7.7 3.0 23.6 4.3 21.5 0.4 6.4
X = the least common alleles joined (DRB1*09, DRB1*10, DRB1*12 and DRB1*16)
*Within each patient group, allele frequencies for those with a non-resolving disease and those with a resolving disease are shown as well.
Grunewald et al. Respiratory Research 2010, 11:25
http://respiratory-research.com/content/11/1/25
Page 3 of 7Strong positive associations were here found for DRB1*14
(OR 2.14, p = 0.005) and DRB1*15 (OR 1.55, p = 0.011).
Among patients with a resolving disease, we noted an
extremely strong positive association with DRB1*03 (OR
5.42, p = 3 × 10
-22), in line with a recent study of ours
[14]. In contrast, we found DRB1*07 to prevent a resol-
ving disease among all patients (OR 0.44, p = 0.009).
Non-Löfgren’s patients (n = 452)
In this group of patients, HLA-DRB1*14 (OR 1.87, p =
0.021) associated with disease, with similar trends for
DRB1*11 (OR 1.48, p = 0.067) and DRB1*15 (OR 1.35,
p = 0.086) (Table 4). In contrast, HLA-DRB1*01 (OR
0.39, p = 5 × 10
-6) and DRB1*03 (OR 0.63, p = 0.017)
protected against disease (Table 3). In particular, HLA-
DRB1*01 (OR 0.34, p = 5 × 10
-6)a n dH L A - D R B 1 * 0 3
(OR 0.47, p = 6 × 10
-4) protected against a non-resol-
ving disease, encompassing 78% of the non-Löfgrens
patients. HLA-DRB1*14 (OR 2.08, p = 0.010) was
instead a risk factor for non-resolving disease, with a
similar tendency for HLA-DRB1*11 (OR 1.51, p = 0.085)
and HLA-DRB1*15 (OR 1.42, p = 0.067). These strati-
fied groups were significantly different with regards to
allele distribution (p = 0.002).
Löfgren’s syndrome patients (n = 302)
HLA-DRB1*03 strongly associated with Löfgren’ss y n -
drome (OR 6.71, p = 2 × 10
-24), and especially with a
r e s o l v i n gf o r mo ft h ed i s e a s e( O R1 1 . 4 2 ,p=8×1 0
-27)
(Table 5). DRB1*03 also tended to protect against a
non-resolving form of Löfgren’s syndrome (OR 0.20, p =
0.086). DRB1*15 was a risk factor for non-resolving dis-
ease in Löfgren’s syndrome patients (OR 3.02, p =
0.016). In analogy with these distinct associations, the
alleles distribution in the two stratified groups was sig-
nificantly different (p = 3.8 × 10
-10).
Discussion
In contrast to most previous studies and in order to bet-
ter reveal genetic associations with sarcoidosis, we here
Table 3 Odds ratios (OR) of HLA-DRB1 alleles in all patients with sarcoidosis as compared to healthy Swedish controls
(n = 1366).
*All patients (n = 754) Non-resolving patients (n = 399) Resolving patients (n = 325)
DRB1 allele OR p-value OR p-value OR p-value
*01 0.61 0.003 0.41 3 × 10
-5 0.87 0.665
*03 1.91 1 × 10
-6 0.45 1 × 10
-4 5.42 3 × 10
-22
*04 0.77 0.086 0.77 0.168 0.78 0.288
*07 0.77 0.165 0.93 0.844 0.44 0.009
*08 0.80 0.353 0.95 0.891 0.60 0.168
*11 1.21 0.368 1.41 0.136 0.98 0.98
*14 1.79 0.017 2.14 0.005 1.20 0.759
*15 1.32 0.067 1.55 0.011 1.01 0.985
x 1.09 0.775 1.22 0.484 0.79 0.573
*Separate figures are shown for all patients, non-resoving patients, and resolving patients.
X = the least common alleles joined (DRB1*09, DRB1*10, DRB1*12 and DRB1*16)
Table 4 Odds ratios (OR) of HLA-DRB1 alleles in patients with non-Löfgren’s sarcoidosis as compared to healthy
Swedish controls (n = 1366).
All non-Löfgren’s patients
(n = 452)
Non-resolving non-Löfgren’s patients
(n = 354)
Resolving non-Löfgren’s patients
(n = 92)
DRB1 allele OR p-value OR p-value OR p-value
*01 0.39 5 × 10
-6 0.34 5 × 10
-6 0.48 0.107
*03 0.63 0.017 0.47 6 × 10
-4 1.23 0.649
*04 0.80 0.238 0.73 0.110 1.04 0.947
*07 0.85 0.489 0.95 0.891 0.44 0.122
*08 0.93 0.852 0.97 0.947 0.79 0.755
*11 1.48 0.067 1.51 0.085 1.51 0.350
*14 1.87 0.021 2.08 0.010 1.13 0.898
*15 1.35 0.086 1.42 0.067 1.10 0.855
x 1.12 0.755 1.26 0.431 0.62 0.467
*Separate figures are shown for all patients, non-resoving patients, and resolving patients.
X = the least common alleles joined (DRB1*09, DRB1*10, DRB1*12 and DRB1*16)
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clinical manifestations, and those without this syndrome.
We found the allele carrier frequencies in these two
patient sub-groups to clearly be quite different. Future
studies on gene associations in sarcoidosis should
accordingly take into account the number of LS patients
in the study group, and preferably investigate the LS
patient group separately. All patients in the present
study represent a large homogeneous population of sar-
coidosis patients derived from one single centre in
Stockholm, Sweden. The vast majority of cases were
seen and clinically evaluated by one of the authors. One
important observation in the present study is that more
than half of all patients developed a non-resolving dis-
ease. In this group of patients, many will develop a
chronic inflammatory disease with sometimes lifelong
need of attention of the health care system. Although
we cannot exclude the possibility that the patient cohort
from our clinical centre is somewhat biased and may
include unusually large numbers of patients with a more
severe disease, in this study population sarcoidosis
seems to be a disease with more profound negative
health effects than previously thought. In other ethnic
groups this may be even more pronounced.
In the entire patient group, especially DRB1*03, but
also DRB1*14 and to some degree DRB1*15 were risk
factors, while DRB1*01 and to some extent DRB1*04
instead protected against disease. Interestingly, associa-
tions between HLA-DRB1 alleles and disease were in
several cases clearly different in the two patient sub-
groups; while DRB1*01 strongly protected against dis-
ease in non-Löfgren’s patients, we found no influence
on Löfgren’s syndrome. DRB1*03 clearly protected
against disease in non-Löfgren’s, but in contrast strongly
increased the risk for Löfgren’ss y n d r o m e .D R B 1 * 1 1
tended to increase the risk for non-Löfgren’sd i s e a s e ,
but had no such influence on Löfgren’ss y n d r o m e .T h e
increased risk for sarcoidosis associated with DRB1*14
o rD R B 1 * 1 5a l s os e e m e dt ob er e s t r i c t e dt on o n - L ö f g -
ren’s disease. Altogether, these results clearly show the
importance of patient phenotyping in order to reveal
true genetic associations with sarcoidosis. Comparing
data from studies on HLA-associations that have been
performed on patient populations including various
mixed patient phenotypes may give false results. The
need for taking patient phenotype into consideration
may in part explain previous heterogeneous results on
HLA-associations with sarcoidosis, as may also too
small sample sizes.
The discrepant and in some cases opposite genetic
associations described here for some of the DRB1 alleles
with non-LS and LS patients are in line with the con-
cept that LS is a distinct disease entity, further sup-
ported by the finding of a variant of CCR2 that was
recently described to associate with LS patients indepen-
dently of DRB1*03 [15] There were however also several
similarities between non-LS and LS patients, especially
regarding the influence of DRB1 alleles on the disease
course. DRB1*03 protected against a non-resolving dis-
ease while DRB1*07 weakly increased the risk for a non-
resolving disease in both patient sub-groups. Both
DRB1*14 and DB1*15 tended to increase the risk for a
non-resolving disease in the two subgroups, though with
a more pronounced influence of DRB1*14 on non-LS
and of DRB1*15 on LS patients. Such similar associa-
tions may reflect a capacity to present specific antigens
that are linked to a more prolonged disease course, or
they may reflect linkages to other genes important for
the immune response and for the typical formation of
non-caseating granulomas, and to the continuing exis-
tence of such granulomas, which in turn could lead to a
longer disease course.
Table 5 Odds ratios (OR) of HLA-DRB1 alleles in patients with Löfgren’s syndrome as compared to healthy Swedish
controls (n = 1366).
All Löfgren’s syndrome patients
(n = 302)
Non-resolving Löfgren’s syndrome patients
(n = 45)
Resolving Löfgren’s syndrome patients
(n = 233)
DRB1 allele OR p-value OR p-value OR p-value
*01 1.12 0.755 1.08 0.929 1.16 0.730
*03 6.71 2 × 10
-24 0.20 0.086 11.42 8 × 10
-27
*04 0.73 0.190 1.12 0.882 0.68 0.165
*07 0.60 0.116 0.80 0.831 0.47 0.067
*08 0.50 0.104 0.71 0.769 0.52 0.183
*11 0.66 0.246 0.47 0.487 0.72 0.443
*14 1.44 0.443 2.87 0.129 1.24 0.775
*15 1.32 0.264 3.02 0.016 1.00 0.995
x 0.96 0.947 1.00 0.999 0.89 0.855
*Separate figures are shown for all patients, non-resoving patients, and resolving patients.
X = the least common alleles joined (DRB1*09, DRB1*10, DRB1*12 and DRB1*16)
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smaller numbers of patients. In a study on three cohorts
of sarcoidosis patients from United Kingdom, Poland, and
the Czech Republic, DRB1*01 was consistently found to
protect against sarcoidosis [21]. Furthermore, DRB1*04
was found to be protective in UK patients only, which was
in agreement with previous reports from Sweden [9],
Japan [22] and Italy [8]. The protective properties of
DRB1*01 and DRB1*04 were suggested to be caused by
the presence in these DRB1 alleles of small hydrophobic
residues at position 11, which is within a pocket of the
antigen-binding groove (pocket 6) and influence the bind-
ing of antigenic peptides [21]. Our present study thus con-
firms the protective effect of especially DRB1*01 in
sarcoidosis, however only in non-Löfgren’ss y n d r o m e
patients. Interestingly, DRB1*01 has also been shown to
protect against multiple sclerosis (MS), i.e. another
immune mediated inflammatory disorder [23].
Several other HLA DRB1 alleles have been shown to
be risk factors. In the previously published largest HLA-
survey, from the “A Case Control Etiologic Study of Sar-
coidosis” (ACCESS) study and including 474 HLA-typed
patients, it was reported that especially DRB1*11 but
also DRB1*12 and DRB1*15 were risk factors for sarcoi-
dosis [24]. We and others have also previously reported
on the increased risk for sarcoidosis associated with
DRB1*03, DRB1*14 and DRB1*15 [9,21,25]. Thus, by
large a pattern of HLA associations with sarcoidosis is
emerging.
In addition, specific HLA alleles can also associate
with the disease course. Previous reports have shown
especially a strong association between HLA-DRB1*03
and Löfgren’s syndrome, and a good prognosis
[6-12,14]. Also HLA-DRB1*1501 (strongly linked to
DQB1*0602) has previously been associated with a
chronic course of sarcoidosis and severe pulmonary sar-
coidosis [9,11,12,26].
The reason for HLA class II associations with disease
is not clear, but is likely due to their pivotal role for
mounting specific immune responses by presenting anti-
gen peptides for T cells, which in sarcoidosis results in
lung accumulation and activation of CD4+ T cells, gran-
uloma formation and in some cases chronic inflamma-
tion and fibrosis. That specific antigen peptide binding
by DRB1 alleles is important in sarcoidosis is supported
by the finding of specific HLA class II amino acid epi-
topes, especially in pocket 4 of the DRB1 molecule, that
correlate with disease. Intriguingly, Arg74 in DRB1
pocket 4 was found to independently correlate with
radiographic stage I [27]. This particular DRB1 pocket 4
is also important for generating accumulations of T cells
expressing the AV2S3 T cell [28], in line with a specific
T cell mediated immune response directed against a
specific antigenic peptide in the lungs of sarcoidosis
patients. Recently, using bioinformatic tools, Saltini et al
suggested that HLA-DRB1 alleles of LS patients could
recognize significantly higher numbers of bacterial anti-
gen epitopes, especially those derived from mycobacteria
[29].
However, the strong linkage disequilibrium (LD) in
this region complicates interpretations of HLA associa-
tions. It may be that the associations between specific
HLA alleles and disease instead reflect associations with
other closely linked genes of importance for immune
responses, such as tumor necrosis factor (TNF) and
lymphotoxin (LT).
For example, DRB1*03 is part of the “8.1 ancestral
haplotype”, which is associated with a number of other
autoimmune diseases, such as myasthenia gravis and
systemic lupus erythematosus. This haplotype includes a
large number of gene variants that may be important
for the immune response, e.g. a defect complement 4
(C4), which could result in a decreased ability to elimi-
nate immune complexes of possible importance for the
development of erythema nodosum caused by deposi-
tion of immune-complexes [30,31].
In conclusion, this study reveals the importance of
sub-grouping sarcoidosis patients when calculating
genetic risk factors, since we here found several distinct
differences between the patient subgroups and describes
new associations between specific HLA-DRB1 alleles
and sarcoidosis. In future studies, as we continue and
collect more patient data, it will be interesting to study
separately subgroups of patients with particular clinical
manifestations and specific organ engagements.
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